
    
      This is an open-label randomized trial in patients with early- stage Triple Negative Breast
      Cancer. Patients will be treated with either paciltaxel alone or paclitaxel with bavituximab.
      Paclitaxel will be given weekly, and bavituximab will be given weekly. All therapy will
      continue for up to twelve doses of treatment followed by standard of care definitive surgical
      resection.
    
  